A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive BCell Acute Lymphoblastic Leukemia

被引：1

作者：

Short, Nicholas J. ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Alvarado, Yesid ^{[1
]}

Burger, Jan A. ^{[1
]}

Jain, Nitin ^{[1
]}

Konopleva, Marina ^{[1
]}

Ravandi, Farhad ^{[1
]}

DiNardo, Courtney D. ^{[1
]}

Masarova, Lucia ^{[1
]}

Sasaki, Koji ^{[1
]}

Thompson, Philip A. ^{[1
]}

Ferrajoli, Alessandra ^{[1
]}

Jacob, Jovitta ^{[1
]}

Milton, Anna ^{[1
]}

Garris, Rebecca ^{[1
]}

Jabbour, Elias J. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-154124

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2299

引用

页数：6

共 50 条

[31] A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study [J].

Brivio, Erica ;

Locatelli, Franco ;

Thano, Adriana ;

Petit, Arnaud ;

Vormoor, Britta Julia ;

Rives, Susana ;

Bielorai, Bella ;

Rossig, Claudia ;

Rizzari, Carmelo ;

Van der Velden, Vincent H. J. ;

Ammerlaan, Anneke C. J. ;

Den Boer, Monique L. ;

Sleight, Barbara ;

Engstler, Gernot ;

Stary, Jan ;

Sirvent, Francisco Jose Bautista ;

Chen-Santel, Christiane ;

Bruno, Benedicte ;

Bertrand, Yves ;

Rialland, Fanny ;

Plat, Genevieve ;

Reinhardt, Dirk ;

Vinti, Luciana ;

von Stackelberg, Arend ;

Zwaan, Christian Michel .

BLOOD, 2020, 136

[32] Measurable Residual Disease in Acute Lymphoblastic Leukemia: Techniques and Therapeutic Utility [J].

Muffly, Lori .

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (07) :419-421

[33] Molecular and cellular markers for measurable residual disease in acute lymphoblastic leukemia [J].

Juarez-Avendano, Gerardo ;

Mendez-Ramirez, Nereida ;

Luna-Silva, Nuria C. ;

Gomez-Almaguer, David ;

Pelayo, Rosana ;

Balandran, Juan C. .

BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2021, 78 (03) :159-170

[34] Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial [J].

Jabbour, Elias ;

Goekbuget, Nicola ;

Advani, Anjali ;

Stelljes, Matthias ;

Stock, Wendy ;

Liedtke, Michaela ;

Martinelli, Giovanni ;

O'Brien, Susan ;

Wang, Tao ;

Laird, A. Douglas ;

Vandendries, Erik ;

Neuhof, Alexander ;

Nguyen, Kevin ;

Dakappagari, Naveen ;

DeAngelo, Daniel J. ;

Kantarjian, Hagop .

LEUKEMIA RESEARCH, 2020, 88

[35] PREDICTING MEASURABLE RESIDUAL DISEASE FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS POSTTRANSPLANTATION [J].

Wang, Yue-Wen ;

Fu, Guo-Mei ;

Xu, Lan-Ping ;

Wang, Yu ;

Cheng, Yi-Fei ;

Zhang, Yuan-Yuan ;

Zhang, Xiao-Hui ;

Liu, Yan-Rong ;

Liu, Kai-Yan ;

Huang, Xiao-Jun ;

Chang, Ying-Jun .

BONE MARROW TRANSPLANTATION, 2024, 59 :498-498

[36] Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia [J].

Ueda, Tomoaki ;

Fukushima, Kentaro ;

Kusakabe, Shinsuke ;

Yoshida, Koki ;

Suga, Makiko ;

Nakai, Ritsuko ;

Koike, Midori ;

Hino, Akihisa ;

Akuta, Keigo ;

Toda, Jun ;

Nagate, Yasuhiro ;

Doi, Yukiko ;

Fujita, Jiro ;

Yokota, Takafumi ;

Hosen, Naoki .

LEUKEMIA RESEARCH REPORTS, 2022, 17

[37] Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment [J].

Marks, David, I ;

van Oostrum, Ilse ;

Mueller, Sabrina ;

Welch, Verna ;

Vandendries, Erik ;

Loberiza, Fausto R. ;

Bohme, Sarah ;

Su, Yun ;

Stelljes, Matthias ;

Kantarjian, Hagop M. .

CANCER MEDICINE, 2019, 8 (13) :5959-5968

[38] GIMEMA ALL2418| UPDATED INTERIM ANALYSIS OF A PHASE IIA STUDY OF FEASIBILITY AND EFFECTIVENESS OF INOTUZUMAB OZOGAMICIN IN ADULT PATIENTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH POSITIVE MINIMAL RESIDUAL DISEASE [J].

Martinelli, G. ;

Piciocchi, A. ;

Chiaretti, S. ;

Papayannidis, C. ;

Salutari, P. ;

Olivieri, A. ;

Zappasodi, P. ;

Rambaldi, A. ;

Fracchiolla, N. ;

Cavallari, M. ;

Soddu, S. ;

Abbenante, M. ;

Candoni, A. ;

Cattaneo, C. ;

Gigli, F. ;

Marino, M. R. ;

Messina, M. ;

Grillo, G. ;

Ferrara, F. ;

Siragusa, S. ;

De Fabritiis, P. ;

Lico, A. ;

Audisio, E. ;

Bonifacio, M. ;

Lemoli, R. M. ;

Mattei, D. ;

Lunghi, M. ;

Cilloni, D. ;

Ferrari, A. ;

Nanni, J. ;

Della Starza, I. ;

Simonetti, G. ;

De Propris, M. ;

Bochicchio, M. T. ;

Vignetti, M. ;

Fazi, P. ;

Marconi, G. .

HAEMATOLOGICA, 2024, 109 :79-80

[39] BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN ALGERIA [J].

Djemai, S. ;

Derki, S. ;

Enzrati, Jalal J. ;

Russell-Smith, T. A. .

VALUE IN HEALTH, 2024, 27 (12) :S83-S84

[40] Risk factors for positive post-transplantation measurable residual disease in patients with acute lymphoblastic leukemia [J].

Wang Yuewen ;

Fu Guomei ;

Xu Lanping ;

Wang Yu ;

Cheng Yifei ;

Zhang Yuanyuan ;

Zhang Xiaohui ;

Liu Yanrong ;

Liu Kaiyan ;

Huang Xiaojun ;

Chang Yingjun .

中华医学杂志英文版, 2025, 138 (09)

← 1 2 3 4 5 →